Intraocular Lymphoma: Current Therapy and Future Trends

2010 ◽  
pp. 485-489
Author(s):  
Christopher J. Calvano ◽  
Stella K. Kim ◽  
Dan S. Gombos
Keyword(s):  
Intraocular Lymphoma ◽  
Current Therapy ◽  
Future Trends

On the origin of the rising incidence of esophageal adenocarcinoma and prediction of future trends

2001 ◽  
Vol 120 (5) ◽  
pp. A30-A30
Author(s):  
J HELM ◽  
J BARTHEL ◽  
D COPPOLA ◽  
P LAZARUS ◽  
S LUTHER ◽  
...  
Keyword(s):  
Esophageal Adenocarcinoma ◽  
Future Trends ◽  
Rising Incidence

Families in Society: Current Research and Future Trends

1996 ◽  
Vol 41 (5) ◽  
pp. 466-467
Author(s):  
Lori A. Ingram
Keyword(s):  
Future Trends

Current Therapy in Childhood Brain Tumors

1985 ◽  
Vol 3 (1) ◽  
pp. 147-164 ◽  
Author(s):  
Michael E. Cohen ◽  
Patricia K. Duffner
Keyword(s):  
Brain Tumors ◽  
Current Therapy ◽  
Childhood Brain Tumors

Future trends in health monitoring of materials

2001 ◽  
Vol 89 ◽  
pp. 31-33
Author(s):  
L. Flandin ◽  
Y. Bréchet ◽  
J.Y. Cavaillé
Keyword(s):  
Health Monitoring ◽  
Future Trends

Extravascular Administration of Factor IX: Potential for Replacement Therapy of Canine and Human Hemophilia B

1997 ◽  
Vol 77 (05) ◽  
pp. 0944-0948 ◽  
Author(s):  
Darla Liles ◽  
Charles N Landen ◽  
Dougald M Monroe ◽  
Celeste M Lindley ◽  
Marjorie s Read ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Vitamin K ◽  
Absorption Rate ◽  
Venous Access ◽  
Factor Ix ◽  
Hemophilia B ◽  
Current Therapy ◽  
Home Therapy ◽  
Routes Of Administration ◽  
Plasma Compartment

SummaryCurrent therapy for hemophilia B requires large intravenous doses of factor IX (F.IX) given in the clinic or at home. Although home therapy is possible for many patients, it is often complicated by factors such as the lack of good venous access. Very little is known about extravascular routes for administering proteins like F.IX (57 kD) or other vitamin K-dependent procoagulant factors into the circulation. Questions about the absorption rate from extravascular administration as well as plasma recovery and bioavailability have arisen recently with the growing availibility of highly purified procoagulant proteins and increased interest in gene therapy of hemophilia B. Therefore, a group of studies were undertaken to determine the absorption rate, plasma recovery, and bioavailability of high purity, human plasma-derived F.IX concentrates administered via extravascular routes in hemophilia B dogs and in one human hemophilia B subject. Five hemophilia B dogs were given human F.IX via either a subcutaneous (SC), intramuscular (IM), intra- peritoneal (IP) or intravenous (IV) route. In a subsequent study, a single SC administration of human F.IX was compared to an identical IV dose of F.IX in the human hemophilia B subject. All extravascular routes of F.IX administration in both the canine and human gave lower levels of circulating plasma F.IX than the IV route, however all routes resulted in measurable F.IX activity. Of the extravascular routes, the IM injection in the canine resulted in a bioavailibility of 82.8%, while the SC injection resulted in a bioavailability of 63.5%. F.IX reached the plasma compartment by all extravascular routes used, confirming that F.IX can be absorbed extravascularly. The duration of measurable F.IX activity following extravascular administration is prolonged beyond that typically seen with IV administration. These data show that significant levels of F.IX may be obtained via SC injection in canine and ‘ human hemophilia B subjects and further highlight the potential of extravascular routes of administration for future experimental and clinical uses of F.IX and other procoagulant proteins.

Comprehensive Study of Blockchain Technology - Architecture, Consensus and Future Trends

2020 ◽  
pp. 319-325
Author(s):  
Shreya Joshi ◽  
Ms Bhavyaa ◽  
Suhani Gupta ◽  
Lalita Luthra
Keyword(s):  
Internet Of Things ◽  
Product Management ◽  
Future Trends ◽  
Deep Dive ◽  
Record Keeping ◽  
Blockchain Technology ◽  
Healthcare Product ◽  
Core Technology ◽  
Technical Challenges ◽  
Comprehensive Study

Blockchain is considered to be a disruptive core technology. Although many researchers have realized the importance of blockchain, but the research of it is still emerging. It is the record-keeping technology behind bitcoin and is one of the hottest and fastest growing skills in the IT sector today. It serves as an immutable ledger which allows transactions to take place in a decentralized man Blockchain-based applications are rising up, covering numerous fields including finance, healthcare, product management, Internet of Things (IoT), and many more. However, there are still some challenges of blockchain technology such as scalability and security problems which need to be overcome. This paper comprises of a comprehensive study of Blockchain technology. We have included here a deep dive into how blockchains work, its architecture, consensus and various applications. Furthermore, technical challenges are briefly listed.

Sign in / Sign up

Export Citation Format

Share Document